Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases. (Q35916658)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852222%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852222%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852222%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Joshua Silverman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852222%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Amparo Wolf

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852222%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Sayyad Zia

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852222%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Rashika Verma

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852222%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Anna Pavlick

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852222%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

John G Golfinos

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852222%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Douglas Kondziolka

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852222%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

6 February 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852222%20AND%20SRC:MED&resulttype=core&format=json

Journal of Neuro-Oncology

7 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852222%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

127

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852222%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

607-615

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852222%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852222%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11060-016-2072-6

7 March 2020

exact match

0 references

cites work

Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Determinants of outcome in melanoma patients with cerebral metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Management of cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Determinants of survival in patients with brain metastases from cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Predictors of survival, neurologic death, local failure, and distant failure after gamma knife radiosurgery for melanoma brain metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Integration of gamma knife surgery in the management of cerebral metastases from melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Vemurafenib and radiation therapy in melanoma brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute Toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Development, Implementation, and Use of a Local and Global Clinical Registry for Neurosurgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Gamma knife radiosurgery in the management of malignant melanoma brain metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

BRAF mutations in advanced cancers: clinical characteristics and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2072-6

Stereotactic radiosurgery for patients with "radioresistant" brain metastases

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26852222

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Metastatic melanoma: a regional review and future directions

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26852222

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11060-016-2072-6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852222%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference